DB05290InvestigationalSmall molecule
SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy. This study was designed to evaluate whether avosentan influences the pharmacokinetics of...
- Mechanism
- Curator reviewed
Avosentan has effect on the concentration levels of ethinylestradiol and progesterone. That’s why it is possible that the contraceptive efficacy of low-dose combination oral contraceptives may be adversely affected during avosentan treatment.
- Primary indication
- Investigated for use/treatment in cardiovascular disorders and neuropathy (diabetic).Curator reviewed
- Code names
- SPP 301
Resolves to
Targets
What you can answer from here — as of April 23, 2025
Which drugs share a target with SPP 301, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account